Literature DB >> 7511086

A role for histones and ubiquitin in lupus nephritis?

F Stöckl1, S Muller, S Batsford, T Schmiedeke, R Waldherr, K Andrassy, Y Sugisaki, K Nakabayashi, T Nagasawa, B Rodriguez-Iturbe.   

Abstract

Glomerulonephritis frequently develops in Systemic lupus erythematosus (SLE) but the pathogenesis is still poorly understood. Experimental evidence now suggests that histones can participate in immune complex formation in lupus nephritis. In a retrospective study, using samples from Northern and Southern Europe, Japan and South America, we searched for glomerular deposits of histones, both in native and ubiquitinated forms, in renal biopsy specimens from 48 patients with SLE and 70 cases of glomerulonephritis from patients without SLE. Positive glomerular immunofluorescent staining was revealed with rabbit antibodies to synthetic peptide 1-21 of histone H3, 22-45 of ubiquitin and to the branched region of ubiquitinated histone H2A (U-H2A) in 65% (31/48), 29% (14/48) and 54% (26/48) of the cases of SLE respectively. In total positive staining with at least one of the antibodies was seen in 36/48 (75%) cases. The staining was granular in nature and was present in capillary and mesangial areas. Only 3% (2/70) of non-SLE renal biopsies revealed positive staining with the above antibodies. None of the biopsy specimens from SLE patients were positive for ss- or ds-DNA, when tested with intercalating dyes. Serum samples were available from 15/48 SLE cases and were analysed with peptides and parent proteins by ELISA; epitopes in the N-terminal regions of core histones and in the C-terminus of histone H1 were often recognised by IgG antibodies in SLE sera, as was ubiquitin and the branched octapeptide of U-H2A. These results support the notion that the nuclear autoantigens histone and ubiquitin may be involved in the induction of glomerulonephritis in human SLE.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511086

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  8 in total

1.  Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents.

Authors:  Matlock A Jeffries; Amr H Sawalha
Journal:  Int J Clin Rheumtol       Date:  2011-08

Review 2.  Epigenetic histone code and autoimmunity.

Authors:  Jürgen Dieker; Sylviane Muller
Journal:  Clin Rev Allergy Immunol       Date:  2010-08       Impact factor: 8.667

3.  Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus.

Authors:  J B Lefkowith; M Kiehl; J Rubenstein; R DiValerio; K Bernstein; L Kahl; R L Rubin; M Gourley
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

4.  Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo.

Authors:  C Kramers; M N Hylkema; M C van Bruggen; R van de Lagemaat; H B Dijkman; K J Assmann; R J Smeenk; J H Berden
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

5.  Decrease of heparan sulfate staining in the glomerular basement membrane in murine lupus nephritis.

Authors:  M C van Bruggen; K Kramers; M N Hylkema; J van den Born; M A Bakker; K J Assmann; R J Smeenk; J H Berden
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

6.  Antibodies to DNA, chromatin core particles and histones in mice with graft-versus-host disease and their involvement in glomerular injury.

Authors:  C Meziere; F Stöckl; S Batsford; A Vogt; S Muller
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

Review 7.  Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis.

Authors:  Pragnesh Mistry; Mariana J Kaplan
Journal:  Clin Immunol       Date:  2016-08-09       Impact factor: 3.969

Review 8.  Breaking immunological tolerance in systemic lupus erythematosus.

Authors:  Elmar Pieterse; Johan van der Vlag
Journal:  Front Immunol       Date:  2014-04-09       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.